Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Relay Therapeutics (RLAY)

October 14, 2024 7:22 AM EDT Send to a Friend
H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $19.00 price target on Relay Therapeutics (NASDAQ: RLAY).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login